

# CONTENTS

---

Preface .....	v
Contributors .....	xi
Color Plates .....	xvii
<b>PART I. GENOMICS, CANCER TARGETS, TRANSCRIPTOMICS, AND GENE EXPRESSION ANALYSIS</b>	
1 Genomic Resources for Cancer Biologists <i>Xuefeng Bruce Ling, Gene Cutler, and Timothy Hoey</i> .....	3
2 Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping <i>Heiko Hermeking</i> .....	19
3 Identification of Novel Cancer Target Antigens Utilizing EST and Genome Sequence Databases <i>Tapan K. Bera, Kristi A. Egland, B. K. Lee, and Ira Pastan</i> .....	31
4 Tree-Based Cancer Classification and Diagnosis Using Gene Expression Data <i>Heping Zhang</i> .....	43
5 From FISH to Proteomics: <i>A Molecular Brush to Define Antitumor Drug Action</i> <i>Balanehru Subramanian, Alexander Nakeff, and Frederick Valeriote</i> .....	53
6 Gene Program Signatures for Papillomavirus E2-Mediated Senescence in Cervical Cancer Cells: <i>Finding the Points of No Return</i> <i>Sarah S. Williams, Bruce J. Aronow, and Susanne I. Wells</i> .....	69
<b>PART II. ADVANCES IN PROTEOMIC AND ENZYMATIC CANCER-PROFILING TECHNOLOGIES</b>	
7 Mass-Spectrometry-Based Proteomics for Cancer Biology <i>Chen Xu and John R. Yates III</i> .....	91
8 Chemical Proteomics in Drug Development <i>Douglas A. Jeffery, Amos Baruch, and Matthew Bogyo</i> .....	109
9 Proteomics-Based Anticancer Drug Discovery <i>K. K. Jain</i> .....	123
10 Cancer Metabolic Phenotype: <i>Exploiting the Cancer Metabolome in Drug Discovery</i> <i>John R. Griffiths and Marion Stubbs</i> .....	135
11 Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imaging <i>Lucy A. Carver and Jan E. Schnitzer</i> .....	151
<b>PART III. CANCER TARGET VALIDATION: CELLULAR APPROACHES</b>	
12 RNA Interference: <i>RNAid for Future Therapeutics?</i> <i>Mustapha Diallo, Katja Schmitz, and Ute Schepers</i> .....	167

13	Image-Based Assays of Cellular Phenotype for Drug Target Discovery and Validation <i>Kris F. Sachsenmeier and Jonathan A. Terrett</i> .....	195
14	Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer <i>David Ljungman and James C. Cusack, Jr.</i> .....	209
15	Targeting Apoptosis Pathways for Cancer Therapy <i>Bharvin K. R. Patel</i> .....	229
<b>PART IV. CANCER TARGET VALIDATION: ANIMAL APPROACHES</b>		
16	Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development <i>Rónán C. O'Hagan, Min Wu, William M. Rideout III, Yinghui Zhou, and Joerg Heyer</i> .....	247
17	Unraveling the Complexity of Oncogenesis Through In Vivo Optical Imaging <i>Pamela Reilly Contag</i> .....	263
18	Innovative Strategies for Improving Engineered Mouse Models of Human Cancer for Preclinical Development <i>Jeffrey J. Martino and Suzie Chen</i> .....	275
19	Use of Adenovirus-Mediated Gene Transfer to Facilitate Biological Annotation of Novel Genes <i>Jeff L. Ellsworth, Andrew Feldhaus, and Steven D. Hughes</i> .....	287
20	Cancer Biology and Transgenic Technology in the Mouse: Bridging the Functional Gap <i>Cindy E. McKinney and Cooduvalli S. Shashikant</i> .....	303
21	Homology-Based Genomic Mining of Growth Factors Implicated in Neoplasia and Nephritides: <i>PDGF-D</i> <i>Gary C. Starling, William J. LaRochelle, and Gulshan Ara</i> .....	323
<b>PART V. CANCER PROGNOSTICS, DIAGNOSTICS, AND BIOMARKERS</b>		
22	Cancer Pharmacogenomics: <i>Predicting Drug Response in the Genomic Era</i> <i>Brian Z. Ring and Huijun Z. Ring</i> .....	339
23	Diagnosis and Treatment of Malignancies Using Gene Expression Profiling <i>Jimmy C. Sung, Alice Y. Lee, and Timothy J. Yeatman</i> .....	359
24	Implications of Epigenetics for Early Cancer Diagnosis and Prevention <i>Mukesh Verma and Sudhir Srivastava</i> .....	365
25	Novel Molecular and Genetic Prognostic Biomarkers in Prostate Cancer <i>Arnab Chakravarti and Gary Guotang Zhai</i> .....	377
26	PSA in Prostate Cancer Diagnosis <i>Pradip Datta</i> .....	393
27	Tumor Targets and Biomarkers in Renal Cell Carcinoma <i>Ivar Bleumer and Peter F. A. Mulders</i> .....	403

## PART VI. EMERGING APPROACHES TO CANCER THERAPY

## VI-A. TARGETING THE VASCULATURE

- 28 Tumor Vasculature as a Target for Cancer Therapy  
*Grzegorz Korpany, Xianming Huang, and Rolf A. Brekken* ..... 415
- 29 Targeting the VEGF/VEGFR Axis for Cancer Therapy  
*Frank A. Scappaticci* ..... 429
- 30 Inhibiting Cancer Angiogenesis With Molecular Therapy  
*Qixin Leng and A. James Mixson* ..... 441

## VI-B. SUPPORTIVE AND ADJUVANT THERAPIES

- 31 Development of Palifermin (rHuKGF) for Mucositis  
*Ping Wei and Catherine L. Farrell* ..... 459
- 32 Immune Modulation: *The B7 Family Cosignaling Molecules as Emerging Targets for Enhancing Cancer Therapy*  
*Sheng Yao and Lieping Chen* ..... 475

## VI-C. TUMOR-TARGETED THERAPIES

- 33 Proteasome Inhibition and Its Clinical Application in Solid Tumors  
*David J. Park and Heinz-Josef Lenz* ..... 493
- 34 Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy  
*Anas Younes and Andrea Cerutti* ..... 509
- 35 Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy  
*Carlos García-Echeverría* ..... 531
- 36 The mTOR Pathway and Its Inhibitors  
*John B. Easton and Peter J. Houghton* ..... 553
- 37 Cyclo-Oxygenase-2 Enzyme and Its Inhibition  
in Tumor Growth and Therapy  
*Zhongxing Liao, Uma Raju, Kathryn A. Mason, and Luka Milas* ..... 571
- 38 Understanding Prostate-Specific Membrane Antigen and Its Implication  
in Prostate Cancer  
*Arundhati Ghosh and Warren D. W. Heston* ..... 597
- 39 Development of a Radiolabeled Monoclonal Antibody  
to Prostate-Specific Membrane Antigen  
*Stanley J. Goldsmith, Shankar Vallabhajosula, Matthew I. Milowsky,  
David M. Nanus, Lale Kostakoglu, and Neil H. Bander* ..... 617
- 40 Monoclonal Antibody Strategies for Targeting HER2  
*Joan Albanell, Jeffrey S. Ross, Linda Pronk, and Pere Gascon* ..... 627
- 41 From XenoMouse® Technology to Panitumumab (ABX-EGF)  
*Xiaodong Yang, Lorin Roskos, C. Geoffrey Davis, and Gisela Schwab* ..... 647

- 42 Development and Evaluation of Cancer Therapeutic Agents  
Targeting TRAIL Receptor 1 and 2  
*Robin C. Humphreys* ..... 659
- 43 Clinical Studies of Immunotherapy With Rituximab (Rituxan®)  
and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®)  
in B-Cell Lymphoid Malignancies  
*Arturo Molina* ..... 677

## **PART VII. INFORMATICS STRATEGIES AND INITIATIVES**

- 44 Informatics Strategies and Initiatives Used in Cancer Research  
*Martin D. Leach* ..... 713
- Index ..... 731



<http://www.springer.com/978-1-58829-425-8>

The Oncogenomics Handbook  
LaRochelle, W.J.; Shimkets, R.A. (Eds.)  
2005, XVII, 750 p., Hardcover  
ISBN: 978-1-58829-425-8  
A product of Humana Press